pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2755Research ArticleОБЗОРЫREVIEWВнебольничные пневмонии тяжелого течения. Современные возможности антибактериальной терапииSevere community-acquired pneumonia. Modern opportunities of antimicrobial therapyДворецкийЛ. И.DvoretskyL. I.ММА им. И.М. СеченоваRussian Federation20032509202102123127Copyright © Дворецкий Л.И., 20212021Дворецкий Л.И.Dvoretsky L.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2755
.
.
ReferencesЯковлев С.В. Моксифлоксацин при тяжелой внебольничной пневмонии: первая возможность монотерапии? Пульмонология 2002; 3: 123-128.Яковлев С.В. Моксифлоксацин при тяжелой внебольничной пневмонии: первая возможность монотерапии? Пульмонология 2002; 3: 123-128.Choudhri S.H., Hollister A.S., Haverstock D. et al. Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. In: 1-st International symposium on resistant gram-positive infections. San Antonio, Texas; 2000. Poster 1-14.Choudhri S.H., Hollister A.S., Haverstock D. et al. Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. In: 1-st International symposium on resistant gram-positive infections. San Antonio, Texas; 2000. Poster 1-14.Drummond М., Finch R., Duprat-Lomon I. et al. Superior outcomes with moxifloxacin IV/PO amoxicillin/clavuianate±ciar- itromycin in the treatment of community-acquired pneumonia. In: 41-st Interscience conference on antimicrobial agents and chemotherapy. Chicago, Illinois; 2001. Poster 864.Drummond М., Finch R., Duprat-Lomon I. et al. Superior outcomes with moxifloxacin IV/PO amoxicillin/clavuianate±ciar- itromycin in the treatment of community-acquired pneumonia. In: 41-st Interscience conference on antimicrobial agents and chemotherapy. Chicago, Illinois; 2001. Poster 864.Drummond М., Becker D., Них M. et al. Earlier discharge of patients treated with moxifloxacin IV /PO monotherapy (MXF) versus amoxiciliin/clavulanat (AMC) ± claritromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare systems. Eur. Respir. J. 2002; 20 (suppl.38): 561S.Drummond М., Becker D., Них M. et al. Earlier discharge of patients treated with moxifloxacin IV /PO monotherapy (MXF) versus amoxiciliin/clavulanat (AMC) ± claritromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare systems. Eur. Respir. J. 2002; 20 (suppl.38): 561S.Finch R., Schurmann D., Collins O. et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 2002; 46 (6): 1746-1754.Finch R., Schurmann D., Collins O. et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 2002; 46 (6): 1746-1754.File T.M., Sergeti G., Player R. et al. A multicenter randomised study comparing the efficacy and safety of intravenous and or oral levofloxacin versus ceftriaxon and or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Ibid. 1997; 41: 1965-1972.File T.M., Sergeti G., Player R. et al. A multicenter randomised study comparing the efficacy and safety of intravenous and or oral levofloxacin versus ceftriaxon and or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Ibid. 1997; 41: 1965-1972.Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify low-risk patients with community acquired-pneumonia. N. Engl. J. Med. 1997; 336: 243-250.Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify low-risk patients with community acquired-pneumonia. N. Engl. J. Med. 1997; 336: 243-250.Fine M.N., Smith M.F., Carson C.A. et al. Prognosis and outcomes of patients with community-acquired pntumonia. J.A.M.A. 1996; 275: 134-142.Fine M.N., Smith M.F., Carson C.A. et al. Prognosis and outcomes of patients with community-acquired pntumonia. J.A.M.A. 1996; 275: 134-142.Fogarty C., Choudhri S.H., Haverstock D. et al. Efficacy of mox- ifloxacin for treatment of community-acquired pneumonia due penicillin-resistant. In: 41-st Interscience conference on antimicrobial agents and chemotherapy. Chicago, Illinois; 2001. Poster 854.Fogarty C., Choudhri S.H., Haverstock D. et al. Efficacy of mox- ifloxacin for treatment of community-acquired pneumonia due penicillin-resistant. In: 41-st Interscience conference on antimicrobial agents and chemotherapy. Chicago, Illinois; 2001. Poster 854.Grossman C., Choudhri S., Haverstock D. et al. Moxifloxacin intravenous-to-oral switch therapy for severe community- acquired pneumonia. In: Chest. Philadelphia, Pennsylvania; 2001. Poster 187.Grossman C., Choudhri S., Haverstock D. et al. Moxifloxacin intravenous-to-oral switch therapy for severe community- acquired pneumonia. In: Chest. Philadelphia, Pennsylvania; 2001. Poster 187.Grossman C., Choudhri S., Haverstock D. et al. Mioxifloxacin (IV/PO) for patients with severe community-acquired pneumonia. In: 39-th Annual meeting of the Infectious Disease Society of America. San Francisco, California; 2001. Poster 124.Grossman C., Choudhri S., Haverstock D. et al. Mioxifloxacin (IV/PO) for patients with severe community-acquired pneumonia. In: 39-th Annual meeting of the Infectious Disease Society of America. San Francisco, California; 2001. Poster 124.Kahn J.B., Wiesinger A., Olson W.H. et al. Levofloxacin vs ceftriaxone sodium and erytromycin in the treatment of patients with community-acquired pneumonia at high risk of mortality. In: Abstracts of 7-th International symposium on new quinolones. Edinburgh, UK; 2001. 45.Kahn J.B., Wiesinger A., Olson W.H. et al. Levofloxacin vs ceftriaxone sodium and erytromycin in the treatment of patients with community-acquired pneumonia at high risk of mortality. In: Abstracts of 7-th International symposium on new quinolones. Edinburgh, UK; 2001. 45.Larsen S., Choudhri S., Haverstock D. et al. Efficacy and safety of sequential (IV to PO) moxifloxacin for treatment of community-acquired pneumonia due to typical pathogens. In: 41-st Interscience conference on antimicrobial agents and chemotherapy. Chicago, Illinois; 2001. Poster 865.Larsen S., Choudhri S., Haverstock D. et al. Efficacy and safety of sequential (IV to PO) moxifloxacin for treatment of community-acquired pneumonia due to typical pathogens. In: 41-st Interscience conference on antimicrobial agents and chemotherapy. Chicago, Illinois; 2001. Poster 865.Mandell L.A., Marrie T.J, Grossman R.E. et al. Canadian guid- lines for the initial management of community-acquired pneumonia. Clin. Infect. Dis. 2000; 31: 383-421.Mandell L.A., Marrie T.J, Grossman R.E. et al. Canadian guid- lines for the initial management of community-acquired pneumonia. Clin. Infect. Dis. 2000; 31: 383-421.Mandell L., Choudhri S.H., Kubin R.Safetyassesment of sequetial IV/PO moxiflozacin in the treatment of patients with community-aquired pneumonia (CAP). In: 11-th European congress of clinical microbiology and infectious diseases. Istanbul, Turkey; 2001. Poster P863.Mandell L., Choudhri S.H., Kubin R.Safetyassesment of sequetial IV/PO moxiflozacin in the treatment of patients with community-aquired pneumonia (CAP). In: 11-th European congress of clinical microbiology and infectious diseases. Istanbul, Turkey; 2001. Poster P863.Norrby S.R., Petermann W., Willcox P.A. et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand. J. Infect. Dis. 1998; 30: 397-404. ’Norrby S.R., Petermann W., Willcox P.A. et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand. J. Infect. Dis. 1998; 30: 397-404. ’Ortqvist A. Treatment of community-aquired lower respiratory tract infections in adults. Eur. Respir. J. 2002; 20 (suppl.36): 40-53.Ortqvist A. Treatment of community-aquired lower respiratory tract infections in adults. Eur. Respir. J. 2002; 20 (suppl.36): 40-53.Ramires J.A. Switch therapy in adult patients with pneumonia. Clin. Pulm. Med. 1995; 2: 327-333.Ramires J.A. Switch therapy in adult patients with pneumonia. Clin. Pulm. Med. 1995; 2: 327-333.
The authors declare that there are no conflicts of interest present.